このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aptevo Therapeutics マネジメント

マネジメント基準チェック /44

Aptevo Therapeutics'の CEO はMarvin Whiteで、 Aug2016年に任命され、の在任期間は 7.83年です。の年間総報酬は$ 873.45Kで、 64.7%給与と35.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.038%を直接所有しており、その価値は$ 934.74 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と7.8年です。

主要情報

Marvin White

最高経営責任者

US$873.4k

報酬総額

CEO給与比率	64.7%
CEO在任期間	7.8yrs
CEOの所有権	0.04%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	7.8yrs

経営陣の近況

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

CEO報酬分析

Aptevo Therapeutics の収益と比較して、Marvin White の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$873k	US$565k	-US$19m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	US$17m
Dec 31 2022	US$1m	US$565k	US$7m
Sep 30 2022	n/a	n/a	US$6m
Jun 30 2022	n/a	n/a	US$6m
Mar 31 2022	n/a	n/a	-US$30m
Dec 31 2021	US$3m	US$565k	-US$29m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$971k	US$498k	-US$31m
Sep 30 2020	n/a	n/a	-US$33m
Jun 30 2020	n/a	n/a	-US$37m
Mar 31 2020	n/a	n/a	-US$41m
Dec 31 2019	US$974k	US$547k	-US$43m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$49m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$1m	US$565k	-US$54m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$35m
Dec 31 2017	US$1m	US$543k	-US$33m

報酬と市場: Marvinの総報酬 ($USD 873.45K ) は、 US市場 ($USD 678.50K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Marvinの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Marvin White (62 yo)

7.8yrs

在職期間

US$873,446

報酬

Mr. Marvin L. White has been Independent Director at Emergent BioSolutions Inc. since 2022 and served as its Director since October 1, 2020 until 2022. Mr. White has been the Chief Executive Officer, Presi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Marvin White	President	7.8yrs	US$873.45k	0.038% $ 468.8
Jeffrey Lamothe	Executive VP & COO	1.3yrs	US$741.59k	0.021% $ 260.7
SoYoung Kwon	Senior VP	2.9yrs	US$654.73k	0.014% $ 179.9
Daphne Taylor	Senior VP & CFO	1.3yrs	データなし	0.010% $ 127.8
Dirk Huebner	Chief Medical Officer	2.4yrs	データなし	データなし

2.4yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: APVOの経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Marvin White	President	7.8yrs	US$873.45k	0.038% $ 468.8
Daniel Abdun-Nabi	Independent Director	7.8yrs	US$73.21k	0.0068% $ 84.8
Zsolt Harsanyi	Independent Director	7.8yrs	US$93.21k	0.0069% $ 85.6
John Niederhuber	Independent Chairman	7.8yrs	US$88.21k	0.0053% $ 66.4
Barbara Kunz	Independent Director	7.8yrs	US$78.21k	0.0049% $ 60.6
Grady Grant	Independent Director	7.8yrs	US$70.71k	0.0049% $ 60.6

7.8yrs

平均在職期間

68.5yo

平均年齢

経験豊富なボード: APVOの取締役会は経験豊富であると考えられます ( 7.8年の平均在任期間)。

Aptevo Therapeutics マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Insufficient new directors

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Insufficient new directors

Insufficient new directors

Recent updates

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Price target increased by 49% to US$671

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

New major risk - Share price stability

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Price target decreased by 33% to US$12.00

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings: EPS exceeds analyst expectations

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to US$18.00

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Consensus revenue estimates fall by 15%

Price target decreased to US$52.50

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Price target decreased to US$59.50

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo gets $50/share takeout offer from shareholder Tang

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Aptevo sells off after clarifying complete response in early-stage study on lead drug

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44